Standard Biotools Stock Performance
LAB Stock | USD 2.48 0.08 3.13% |
The entity has a beta of 1.19, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Standard Biotools has an expected return of -0.0298%. Please make sure to validate Standard Biotools jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if Standard Biotools performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Standard Biotools has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Standard Biotools is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (3.12) | Five Day Return (4.25) | Year To Date Return 11.71 | Ten Year Return (90.34) | All Time Return (82.31) |
1 | Acquisition by Hanjoon Kim of 70702 shares of Standard Biotools subject to Rule 16b-3 | 04/05/2024 |
2 | Is It Time To Consider Buying Standard BioTools Inc. | 04/09/2024 |
3 | Disposition of 196512 shares by Michael Egholm of Standard Biotools subject to Rule 16b-3 | 04/12/2024 |
4 | Standard BioTools GAAP EPS of -0.27 misses by 0.15, revenue of 45.54M misses by 0.46M | 05/08/2024 |
5 | Standard BioTools Inc. Q1 2024 Earnings Call Transcript | 05/13/2024 |
6 | Disposition of 18779 shares by Jeffrey Black of Standard Biotools at 2.54 subject to Rule 16b-3 | 05/15/2024 |
7 | Acquisition by Casdin Partners Master Fund, L.p. of 500000 shares of Standard Biotools at 2.5419 subject to Rule 16b-3 | 05/16/2024 |
8 | Acquisition by Casdin Partners Master Fund, L.p. of 352072 shares of Standard Biotools at 2.5621 subject to Rule 16b-3 | 05/17/2024 |
9 | Acquisition by Hanjoon Kim of 333333 shares of Standard Biotools subject to Rule 16b-3 | 05/20/2024 |
10 | Acquisition by Casdin Partners Master Fund, L.p. of 350000 shares of Standard Biotools at 2.5598 subject to Rule 16b-3 | 05/21/2024 |
11 | Casdin Partners master fund L.P. buys 1.54m of Standard Biotools shares | 05/22/2024 |
12 | Acquisition by Casdin Partners Master Fund, L.p. of 100000 shares of Standard Biotools at 2.6 subject to Rule 16b-3 | 05/23/2024 |
13 | My Green Lab and Impact Laboratories Welcome Jennifer Edson as New CFO Accelerating Their Shared Mission to Green Science | 05/29/2024 |
14 | Insider Trading | 06/02/2024 |
Begin Period Cash Flow | 81.3 M |
Standard |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 258.00 in Standard Biotools on March 4, 2024 and sell it today you would lose (10.00) from holding Standard Biotools or give up 3.88% of portfolio value over 90 days. Standard Biotools is generating negative expected returns assuming volatility of 2.5518% on return distribution over 90 days investment horizon. In other words, 22% of stocks are less volatile than Standard, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0117
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | LAB |
Estimated Market Risk
2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
-0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Standard Biotools is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding Standard Biotools to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
Return On Equity | -0.23 | ||||
Return On Asset | -0.0939 | ||||
Profit Margin | (0.71) % | ||||
Operating Margin | (0.29) % | ||||
Current Valuation | 273.29 M | ||||
Shares Outstanding | 369.92 M | ||||
Price To Earning | (2.52) X | ||||
Price To Book | 5.87 X | ||||
Price To Sales | 10.03 X | ||||
Revenue | 106.34 M | ||||
Gross Profit | (1.45 M) | ||||
EBITDA | (47.86 M) | ||||
Net Income | (74.66 M) | ||||
Cash And Equivalents | 81.31 M | ||||
Cash Per Share | 2.68 X | ||||
Total Debt | 98.21 M | ||||
Debt To Equity | 0.38 % | ||||
Current Ratio | 5.87 X | ||||
Book Value Per Share | 1.23 X | ||||
Cash Flow From Operations | (43.29 M) | ||||
Earnings Per Share | (1.00) X | ||||
Market Capitalization | 917.4 M | ||||
Total Asset | 323.07 M | ||||
Retained Earnings | (1 B) | ||||
Working Capital | 48.89 M | ||||
About Standard Biotools Performance
To evaluate Standard Biotools Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Standard Biotools generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Standard Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Standard Biotools market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Standard's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 134.09 | 197.10 | |
Return On Tangible Assets | (0.35) | (0.36) | |
Return On Capital Employed | (0.29) | (0.31) | |
Return On Assets | (0.23) | (0.24) | |
Return On Equity | (0.46) | (0.48) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Standard Biotools generated a negative expected return over the last 90 days | |
Standard Biotools has high likelihood to experience some financial distress in the next 2 years | |
The company reported the last year's revenue of 106.34 M. Reported Net Loss for the year was (74.66 M) with loss before taxes, overhead, and interest of (1.45 M). | |
Standard Biotools has about 81.31 M in cash with (43.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Standard Biotools has a poor financial position based on the latest SEC disclosures | |
Roughly 73.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: My Green Lab and Impact Laboratories Welcome Jennifer Edson as New CFO Accelerating Their Shared Mission to Green Science |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.Note that the Standard Biotools information on this page should be used as a complementary analysis to other Standard Biotools' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Standard Biotools' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 0.954 | Quarterly Revenue Growth (0.14) | Return On Assets (0.09) | Return On Equity (0.23) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.